




Revolutionizing NSCLC Diagnostics
EGFR ALK ROS1 RET METex14



YOUR PATIENTS, OUR PRIORITY

Guiding Them to the Right Therapy
within Hours



THINK IDYLLA™
BECAUSE TIME MATTERS

Time is of the Essence in Lung Cancer

Speed up your therapy decisions for better patient outcomes¹

Test for **EGFR, ALK, ROS1, RET and METex14**
in only **3 hours** and immediately start the **right**
targeted therapy for >90% of your patients
with first-line **actionable** biomarkers.²

EGFR

ALK

ROS1

RET

METex14



Idylla™ - Because time matters



Idylla™ helps save lives

Patients receive sub-optimal treatment, rapidly deteriorate or sometimes even die while waiting for their biomarker test results.³



Idylla™ alleviates patient anxiety

Idylla™ allows them to focus on their well-being.⁴



Idylla™ follows international guidelines

Idylla™ enables you to practice Precision Medicine according to international guidelines (e.g. ESMO and NCCN).^{2,5}

Idylla™ - A technology you can rely on

- ✓ Strong scientific evidence (>200 publications)
- ✓ Proven high performance
- ✓ Low failure rate
- ✓ CE-IVD



“ Our experience is fantastic. Idylla™ allows us to have an ultra-fast and reliable panel of biomarkers useful in therapeutic decision-making for the main molecular targets in lung cancer.

Dr. Antonio Calles, Medical Oncologist,
Hospital Universitario Gregorio Marañón, Spain

Biocartis NV
Mechelen, Belgium
+32 15 632 888

www.biocartis.com
customerservice@biocartis.com

Follow us on   

- (1) Aggarwal, C., et al. (2023). Association Between Availability of Molecular Genotyping Results and Overall Survival in Patients With Advanced Non-squamous Non-Small-Cell Lung Cancer. *JCO Precision Oncology*, 7.
- (2) Hendriks, L. E., et al. (2023). Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. *Annals of Oncology: Official Journal of the European Society for Medical Oncology*, 34(4), 339–357.
- (3) Finall, A., et al. (2022). Integration of rapid PCR testing as an adjunct to NGS in diagnostic pathology services within the UK: evidence from a case series of non-squamous, non-small cell lung cancer (NSCLC) patients with follow-up. *Journal of Clinical Pathology*, 76, 391–399.
- (4) Wheelodon, L., et al. (2022) Use of the Biocartis Idylla™ Platform for the Detection of Epidermal Growth Factor Receptor, BRAF and KRAS Proto-Oncogene Mutations in Liquid-Based Cytology Specimens from Patients with Non-Small Cell Lung Carcinoma and Pancreatic Adenocarcinoma. *Journal of Molecular Pathology*, 3(2), 110–114.
- (5) NCCN Clinical Practice Guidelines in Oncology. Non-Small Cell Lung Cancer Version 7.2024

Idylla™ Platform and Idylla™ EGFR Mutation Test (A0270/6) are CE-marked in Europe in compliance with EU IVD Regulation 2017/746 (IVDR). Idylla™ EGFR Mutation Test (A0060/6) & Idylla™ GeneFusion Panel are CE-marked in Europe in compliance with the EU IVD Directive 98/79/EC. For more information on the acceptable use and licenses of Idylla™ products, please visit www.biocartis.com/en/license-statements. Biocartis and Idylla™ are registered trademarks in Europe, the US and many other countries. The Biocartis and Idylla™ trademarks and logos are used trademarks owned by Biocartis NV. Idylla™ is available for sale in Europe, the US and many other countries. Please check availability with a Biocartis representative. © May 2025, Biocartis NV. All rights reserved.